Clinical Trial Goal
To find out:
- The highest dose of VMD-928 that’s safe to give
- If VMD-928 is safe and works well to treat AML or NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 - 80 years old
- Have AML or NHL that has relapsed or is refractory, and there are no more standard treatments available. Some examples of NHL are:
- Burkitt lymphoma
- Cutaneous T-cell lymphoma (CTCL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone B-cell lymphoma (MZL)
- Peripheral T-cell lymphoma (PTCL)
- Small lymphocytic lymphoma (SLL)
- Waldenström's macroglobulinemia
- Other non-Hodgkin lymphoma (NHL)
- Other T-cell lymphoma
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
VMD-928 is a small molecule inhibitor that blocks TrkA in certain cells.
You’ll get:
You’ll get:
- VMD-928 – A pill that you take by mouth 1 time each day. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for 8 months or as long as you’re in the trial.
The Food and Drug Administration (FDA) has not yet approved VMD-928.
Locations
Sponsors
lead: VM Oncology, LLC
